EPS8L3 Polyklonaler Antikörper
EPS8L3 Polyklonal Antikörper für WB, Indirect ELISA
Wirt / Isotyp
Kaninchen / IgG
Getestete Reaktivität
human
Anwendung
WB, Indirect ELISA
Konjugation
Unkonjugiert
Kat-Nr. : 32571-1-PBS
Synonyme
Geprüfte Anwendungen
Produktinformation
32571-1-PBS bindet in WB, Indirect ELISA EPS8L3 und zeigt Reaktivität mit human
| Getestete Reaktivität | human |
| Wirt / Isotyp | Kaninchen / IgG |
| Klonalität | Polyklonal |
| Typ | Antikörper |
| Immunogen | EPS8L3 fusion protein Ag38525 |
| Vollständiger Name | EPS8-like 3 |
| Berechnetes Molekulargewicht | 67kDa,593aa |
| Beobachtetes Molekulargewicht | 65 kDa |
| GenBank-Zugangsnummer | NM_001319952.1 |
| Gene symbol | EPS8L3 |
| Gene ID (NCBI) | 79574 |
| Konjugation | Unkonjugiert |
| Form | Liquid |
| Reinigungsmethode | Antigen-Affinitätsreinigung |
| Lagerungspuffer | PBS only |
| Lagerungsbedingungen | Store at -80°C. 20ul Größen enthalten 0,1% BSA. |
Hintergrundinformationen
EPS8L3 (epidermal growth factor receptor kinase substrate 8-like protein 3) is a member of the EPS8 family, encoding a protein associated with the epidermal growth factor receptor (EGFR) signaling pathway. Studies have shown that EPS8L3 is highly expressed in a variety of tumors, such as hepatocellular carcinoma (HCC), pancreatic cancer, and gastric cancer, and is closely associated with tumor proliferation, migration, and invasive ability. It promotes tumor cell proliferation and inhibits apoptosis by activating GSK3β and PI3K/AKT/mTOR signaling pathways. In addition, high expression of EPS8L3 is associated with poor prognosis in tumor patients and may serve as a biomarker for tumor diagnosis and prognostic assessment. Due to its important role in tumors, EPS8L3 is considered a potential therapeutic target, and its inhibition may enhance the efficacy of multi-target kinase inhibitors.

